Bonitobio
28 employees on LinkedIn · 2 known investors
Find your way into Bonitobio
162 people in our graph share verified history with the Bonitobio team — schools, employers, funds. One of them is your warm intro.
Bonito develops encoded library and live-cell selection technologies to discover delivery ligands, generating high signal-to-noise data on membrane-bound targets to train AI models for precision drug delivery. The company combines functional selections with AI to turn physical delivery experiments into programmable ligand discovery.
Also known as Bonito · Bonito Biosciences
Founders & leadership
Investors · 2
Company profile
researched Aug 2026Bonito Biosciences is a privately held biotechnology company based in Waltham, Massachusetts, working on technologies to enable delivery of macromolecules — particularly oligonucleotides — to extrahepatic cells and tissues. The company describes delivery as an unsolved problem and positions itself as building a data foundation for programmable oligonucleotide delivery.
Its platform pairs giga-scale encoded molecular libraries with live-cell functional selections that screen for actual delivery rather than binding alone, generating proprietary biological datasets that feed an iterative, AI-enabled discovery loop. Bonito states it rebuilt both encoded library and live-cell selection technologies specifically for delivery ligand discovery in order to improve signal-to-noise.
Therapeutic focus areas span small molecule ligands designed as low molecular weight delivery systems for a given cell target, antibody agent ligands including antibody fragments and bispecifics aimed at harder delivery challenges, and target-agnostic approaches for identifying novel cellular access points. Candidate ligands are selected for functional uptake and paired with oligotherapeutic payloads.
Business model
Discovery-platform biotechnology company developing delivery ligands and oligonucleotide therapeutics from its encoded library and functional selection technologies; source material does not detail commercial arrangements.
Traction
Third-party company profiles list a staff size in the 10-50 range as of 2025, including leadership in biology, protein biochemistry and data science/ML alongside CEO and founder Richard Wagner.
▸Full profile — market position, technology, go-to-market, geography
Market position
Early-stage private company in the biotechnology research sector, founded in 2022 and headquartered in Massachusetts, working on extrahepatic delivery of oligonucleotides.
The company states it rebuilt encoded library and live-cell selection technologies from the ground up specifically for delivery ligand discovery, selecting for functional uptake rather than binding in order to improve signal-to-noise in the resulting datasets.
Technology
Encoded libraries providing giga-scale molecular diversity are combined with live-cell functional selections that select for delivery rather than binding, producing high-dimensional datasets used to train AI models for delivery biology. Outputs include small molecule ligands, antibody fragments and bispecifics, and target-agnostic approaches to identifying cellular entry points, each paired with oligotherapeutic payloads.
Go-to-market
Developers and programs requiring delivery of oligonucleotide therapeutics to cells and tissues outside the liver.
Geography
Headquartered at 852 Winter St, Waltham, Massachusetts, United States.
Compiled by commissioned research from 5 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
▸Research sources · 5
primary sources listed
- Bonitobiobonitobio.com · web
5 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Bonitobio do?
- Bonito Biosciences builds encoded-library and functional-selection platforms to discover ligands for oligonucleotide delivery.
- Who founded Bonitobio?
- Bonitobio was founded by Richard Wagner.
- Who are Bonitobio's investors?
- Bonitobio's investors include JAZZ Venture Partners, Lightstone Ventures.